Navigating the ever-evolving landscape of pediatric care means staying ahead of clinical developments, regulatory shifts, and therapeutic breakthroughs—each with the potential to reshape how we ...

The designations follow the FDA acceptance of IND application for ABO-101 to treat PH1, with a phase 1/2 study planned in the first half of 2025. The FDA has granted a pair of designations, both ...

Panelists discuss the 2023 American Academy of Allergy, Asthma & Immunology/ American College of Allergy, Asthma & Immunology (AAAAI/ACAAI) Joint Task Force guidelines, highlighting treatment options ...

Panelists discuss the goals of treating atopic dermatitis, focusing on symptom control and quality of life, with treatment differing for children and adults, and emphasize using assessment tools such ...

As a biosimilar to Actemra, tocilizumab-anoh in both IV and SC formulation is approved to treat rheumatoid arthritis, pJIA, sJIA, COVID-19, and giant cell arteritis. The FDA recently approved ...

The primary and all key secondary endpoints were met compared to cream vehicle in the phase 3 DELTA TEEN trial. LEO Pharma A/S has reported positive phase 3 data for delgocitinib (Anzupgo) 20 mg /g ...

Application submission is based on positive phase 3 data that demonstrated improvement in patients with type 2 and 3 SMA receiving current standard of care. Scholar Rock has submitted a biologics ...

Tina Tan, MD discusses the increased outbreaks of norovirus this year ...

Tina Tan, MD discusses the increased outbreaks of norovirus this year ...

Tina Tan, MD discusses the increased outbreaks of norovirus this year ...

Tina Tan, MD discusses the increased outbreaks of norovirus this year ...

ARS launches program to provide free neffy in eligible K-12 schools ...